Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-aged women. This syndrome is characterized by its heterogeneous presentation including oligoovulation, hyperandrogenism and polycystic ovary morphology. Moreover, women with PCOS exhibit metabolic dysfunction and have an increased risk of type 2 diabetes mellitus. The treatment approach is dependent on the presenting phenotype. Hormonal contraceptives are the first-line management for menstrual abnormalities and androgen excess symptoms, whereas clomiphene is the first-line therapy for infertility. Metformin is beneficial for metabolic abnormalities and menstrual irregularities.